Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001982168 | SCV002210524 | pathogenic | Spastic paraplegia | 2022-06-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SACS protein in which other variant(s) (p.Tyr4538*) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with SACS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg919Glufs*26) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 3661 amino acid(s) of the SACS protein. |
Baylor Genetics | RCV004571648 | SCV005055546 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2024-01-05 | criteria provided, single submitter | clinical testing |